11/29/2023 0 Comments Cutaneous tcel lymphoma![]() The purpose of this study is to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial studies how well giving ruxolitinib phosphate (oral JAK inhibitor INCB18424) works in treating patients with relapsed or refractory diffuse large B-cell or peripheral T-cell non-hodgkin lymphoma and are ineligible to stem cell transplant or have recurrent disease after stem cell transplant. Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma.The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. To assess the efficacy of CTX130 as measured by objective response rate (ORR) in the following 2 expansion arms, according to Lugano response criteria (Cheson et al., 2014) or International Society for Cutaneous Lymphomas (ISCL) response criteria (Olsen et al., 2011) To assess the safety of escalating doses and/or dosing regimens of CTX130 in subjects with relapsed/refractory T or B cell malignancies and to determine one or more recommended Part B dose (RPBD) regimens The primary objectives of this study are: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM).The purpose of this study is to create a cutaneous lymphoma tissue repository. This is a highly significant first step in collecting specimens for future analysis to understand the underlying drivers of disease. The purpose of this trial is to evaluate the antitumor activity of Pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy. Trial Using Keytruda as Initial Therapy in the Treatment of Advanced Mycosis Fungoides.The activated drug may kill cancer cells. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides.Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN ![]() Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma.To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma.The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |